Vaccine renaissance (original) (raw)

Nature Reviews Microbiology volume 5, pages 478–481 (2007)Cite this article

Abstract

Vaccines are one of the most useful and cost-effective tools for reducing the morbidity and mortality that are associated with infectious diseases. Here, Jeffrey Almond discusses the selection of articles in this Focus issue, in the context of the challenges and opportunities facing vaccine developers today.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Jones, T. Vaccines against human papilloma viruses. Curr. Opin. Investig. Drugs 7, 699–701 (2006).
    CAS PubMed Google Scholar
  2. Rappuoli, R. & Covacci, A. Reverse vaccinology and genomics. Science 302, 602 (2003).
    Article CAS PubMed Google Scholar
  3. Pizza, M. et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816–1820 (2000).
    Article CAS PubMed Google Scholar
  4. Kelly, D. F. & Rappuoli, R. Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv. Exp. Med. Biol. 568, 217–223 (2005).
    Article PubMed Google Scholar
  5. Hensel, M. et al. Simultaneous identification of bacterial virulence genes by negative selection. Science 269, 400–403 (1995).
    Article CAS PubMed Google Scholar
  6. Shea, J. E., Santangelo, J. D. & Feldman, R. G. Signature-tagged mutagenesis in the identification of virulence genes in pathogens. Curr. Opin. Microbiol. 3, 451–458 (2000).
    Article CAS PubMed Google Scholar
  7. Meinke, A., Henics, T., Hanner, M., Minh, D. B. & Nagy, E. Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. Vaccine 23, 2035–2041 (2005).
    Article CAS PubMed Google Scholar
  8. Poehling, K. A. et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295, 1668–1674 (2006).
    Article CAS PubMed Google Scholar
  9. Garland, S. M. et al. An evaluation of non-inferiority in antibody response to human papillomavirus (HPV) 16 in subjects vaccinated with monovalent (HPV 16) and quadrivalent (HPV 6,11,16,18) L1 virus-like particle vaccines. Clin. Vaccine Immunol. 11 Apr 2007 (doi:10.1128/CVI.00478-06v1).
  10. Rothman, K. J., Young, X. Y. & Arellano, F. Age dependence of the relation between reassortant rotavirus vaccine (RotaShield) and intussusception. J. Infect. Dis. 193, 898 (2006).
    Article PubMed Google Scholar
  11. Parashar, U. D. & Glass, R. I. Progress toward rotavirus vaccines. Science 312, 851–852 (2006).
    Article CAS PubMed Google Scholar
  12. O'Ryan, M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev. Vaccines 6, 11–19 (2007).
    Article CAS PubMed Google Scholar
  13. Matson, D. O. The pentavalent rotavirus vaccine, RotaTeq. Sem. Ped. Infect. Dis. 17, 195–199 (2006).
    Article Google Scholar
  14. Kaslow, D. C. Biological feasibility of developing prophylactic vaccines for viral pathogens. Hum. Vaccin. 3, 1–7 (2007).
    Article CAS PubMed Google Scholar

Download references

Author information

Authors and Affiliations

  1. sanofi pasteur, 1541 Avenue Marcel Mérieux, Marcy L'Etoile, 69280, France
    Jeffrey W. Almond

Ethics declarations

Competing interests

Jeffrey W. Almond is Head of Research and External R&D at sanofi pasteur.

Rights and permissions

About this article

Cite this article

Almond, J. Vaccine renaissance.Nat Rev Microbiol 5, 478–481 (2007). https://doi.org/10.1038/nrmicro1702

Download citation

This article is cited by